Business Trends

Sep 01, 2005
BioPharm International
By BioPharm International Editors
As a company that performs site selection for biopharmaceutical companies worldwide, Fluor Global Location Strategies has witnessed one country truly distinguishing itself from the competition as a worldwide leader in the industry: the United Kingdom. The global competition for biotech investments has been at a fever pitch over the past few years, with varied results.
Sep 01, 2005
BioPharm International
Formal process and operation improvement activities are being employed in almost every biopharmaceutical manufacturing company, according to a recent survey conducted by Tefen Ltd and Millipore Corporation. The industry-wide survey was conducted to assess current biopharmaceutical operations excellence (OpEx) trends and needs, as well as OpEx perceptions and expectations related to industry suppliers.
Aug 10, 2005
BioPharm International
By BioPharm International Editors
Your research and development team has just shouted "Eureka!" after long and expensive years of research, exclaiming they have developed a next-generation pain reliever. What do you do next? This article explores and suggests your next steps and identifies pertinent questions to ask a patent attorney. The focus is on intellectual property; this article does not address the myriad regulatory issues that must be resolved.
Aug 10, 2005
BioPharm International
By BioPharm International Editors
Biopharmaceutical companies need to consider intellectual property issues early on, even at the start-up stage.
Aug 10, 2005
BioPharm International
By BioPharm International Editors
Trademark protection in the US is based on a dual system of federal and state laws.
Aug 10, 2005
BioPharm International
By BioPharm International Editors
Patents are litigated in the biopharmaceutical industry perhaps more often than any other form of IP
Aug 10, 2005
BioPharm International
By BioPharm International Editors
The Interface of America's Antitrust and Intellectual Property Laws
Aug 10, 2005
BioPharm International
By BioPharm International Editors
Historically, the big pharmaceutical companies (Big Pharma) have sought to feed their marketing machines by manufacturing blockbuster drugs—chemical-based, one-type-fits-all products that treat chronic conditions such as heart disease or arthritis. This approach has yielded recurring revenue streams from large patient populations. In contrast, biotechnology companies typically have created protein-based drugs,or biologics, to treat acute or niche conditions and diseases. With few exceptions (such as the biotech giant Amgen), biotech companies have foregone doing the marketing and sales of their drugs themselves, and have, instead, relied on others to perform their marketing and sales functions.
Aug 01, 2005
BioPharm International
By BioPharm International Editors
Successful acquisition of funding from venture capital (VC) partnerships requires a carefully planned, well-executed marketing campaign. You are, after all, selling ownership interests in your company when you seek VC investors. This sale requires an attractive product, nicely packaged, and presented in a way that allows the potential customer to understand and appreciate its value. The attractiveness of your company is the sum of many factors including revenue potential, intellectual property estate, time-to-milestones, existing competition, ease of entry, quality of management, and the perceived interest in your work by "the big guys" in your sector. Every potential venture investor will not perceive your company the same way.
Aug 01, 2005
BioPharm International
By BioPharm International Editors
Scotland has a ready pool of skilled workers for companies seeking to conduct business in our country.
native1_300x100
lorem ipsum